Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00850044 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1
A Phase 1 study of HCV Infection, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
- 1
- Study location
NCT00850044: Completed Phase 1 study of HCV Infection, sponsored by AbbVie.
NCT00850044 is a Phase 1 study of HCV Infection that has completed, run by AbbVie. The registered enrollment target is 87 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00850044, a Phase 1 study of HCV Infection, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the pharmacokinetic and safety profiles of an experimental HCV protease inhibitor with and without ritonavir in healthy volunteers.
Conditions Studied
Interventions
- DRUG ritonavir
- DRUG ABT-450
- DRUG placebo for ABT-450
- DRUG Placebo for ritonavir
Study Locations (1)
Illinois
- Site Reference ID/Investigator# 15981 - Waukegan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2009-02 |
| Phase | Phase 1 |
What the finished NCT00850044 record still lists
NCT00850044 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% higher).
The record links to 1 condition, with HCV Infection appearing as the primary indexed condition, and to 4 interventions - of which ritonavir is the first listed.
NCT00850044 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00850044 about?
NCT00850044 is a clinical study titled "Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1". The purpose of this study is to determine the pharmacokinetic and safety profiles of an experimental HCV protease inhibitor with and without ritonavir in healthy volunteers.
What is the current status of trial NCT00850044?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2009-02.
What conditions does trial NCT00850044 study?
This clinical trial studies the following conditions: HCV Infection.
What interventions are being tested in trial NCT00850044?
The interventions under investigation include: ritonavir (DRUG), ABT-450 (DRUG), placebo for ABT-450 (DRUG), Placebo for ritonavir (DRUG).
Who is sponsoring clinical trial NCT00850044?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00850044 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HCV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00850044's enrollment target sits among peer trials
87 651st of 2000 higher than 1,349 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia